Monitoring and Follow-Up of Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma should be monitored every 3 months during the first year to establish disease evolution pattern, then every 4-6 months if stable in year two, and every 6-12 months thereafter if no progression is detected 1, 2.
Initial Baseline Workup
At diagnosis, perform a comprehensive baseline assessment including:
- Laboratory studies: CBC, serum calcium, creatinine, albumin, total protein with serum protein electrophoresis (M-protein quantitation), 24-hour urine protein electrophoresis, serum and urine immunofixation, serum free light chain measurement with ratio, and β2-microglobulin 1
- Bone marrow evaluation: Bone marrow aspirate and biopsy (mandatory at baseline) 2
- Imaging: Skeletal survey (mandatory) and MRI of thoracic-lumbar spine and pelvis (recommended, as it can detect occult lesions and predict more rapid progression) 1, 2
First Year Surveillance Strategy
Repeat clinical examination and laboratory studies at 3 months after initial diagnosis 1. If stable, confirm SMM diagnosis and continue:
- Every 3 months for the entire first year with CBC, biochemical survey (creatinine, calcium, albumin), hemoglobin, and serum/urine M-protein levels 1, 2
- This intensive first-year monitoring is critical to establish whether the patient has evolving versus non-evolving disease—a distinction that fundamentally changes prognosis and subsequent monitoring intensity 1
Risk-Stratified Follow-Up After Year One
High-Risk Patients (Closer Monitoring)
Continue every 4-6 months if you identify:
- M-protein >3 g/dL AND bone marrow plasma cells >10%
- ≥95% phenotypically abnormal bone marrow plasma cells
- Immunoparesis present
- Evolving disease pattern (median time to progression ~1.5 years)
- Abnormal free light chain ratio 1, 2
Lower-Risk Patients (Less Frequent Monitoring)
Extend to every 6-12 months if:
- Only M-protein OR bone marrow plasma cell criteria met (not both)
- <95% phenotypically aberrant plasma cells without immunoparesis
- Non-evolving disease pattern (median time to progression ~4 years)
- Beyond 5 years from diagnosis 1
What to Monitor at Each Visit
Standard surveillance includes:
- Hemoglobin level (most frequent and reliable indicator of progression)
- Serum M-protein and urine M-protein levels
- Serum calcium and creatinine
- Complete blood count 1, 2
When to Perform Full Re-Evaluation
Only perform bone marrow aspirate and skeletal survey when there is reasonable suspicion of progression, specifically:
- Progressive decrease in hemoglobin (most reliable indicator)
- Development of soft-tissue plasmacytomas
- Significant skeletal involvement or new bone pain
- Increased serum calcium
- Rising serum creatinine
- Evidence of progression in routine laboratory studies 1, 2
Critical Management Principles
Do not treat until progressive disease with end-organ damage is evident 1. This watchful waiting approach is particularly important for non-evolving SMM patients who have a median time to progression of 4 years, versus evolving variant with median time to progression of only 1.5 years.
Additional Recommendations
- Pneumococcal vaccination may be helpful, particularly in patients with high IgG levels and decreased IgA and/or IgM 1
- Patient counseling: Inform patients there is currently no indication for immediate treatment but they will likely require therapy in the future 1
Common Pitfalls to Avoid
The 2010 IMWG guidelines 1, 2 acknowledge that "there are no formal guidelines concerning evaluation and follow-up for patients with SMM" and that "data are lacking to effectively guide the frequency of follow-up." However, the structured approach above represents the consensus expert recommendations. The key pitfall is over-monitoring low-risk patients or under-monitoring high-risk patients—risk stratification in the first year is essential to avoid both extremes.